Breaking News

Novasep Expands Commercial ADC Manufacturing Plant

New HPAPI capacity at Le Mans facility boosts capabilities for anti-cancer therapies 


Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novasep has invested $5.5 million to expand its highly potent active pharmaceutical ingredients (HPAPI) manufacturing capabilities at its Le Mans facility in France. The expansion has been fully qualified and is now being used to scale up validation of a commercial ADC (antibody drug conjugate) payload. 
 
   HPAPI products must be produced under very strict regulatory conditions to prevent API substance from cross contamination and protect operators from the highly active properties of these pr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters